Rheumatoid Arthritis Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, France, China - Size and Forecast 2024-2028

Published: Oct 2023

Pages: 162

SKU: IRTNTR73313

Snapshot

Rheumatoid Arthritis (RA) Drugs Market Forecast 2024-2028

The global rheumatoid arthritis (RA) drugs market size is estimated to grow by USD 16.05 billion at a CAGR of 7.5% between 2023 and 2028. Rheumatoid arthritis is a chronic autoimmune disease that primarily affects the joints. There are various types of drugs used in the treatment of rheumatoid arthritis, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers (biologics). The rheumatoid arthritis drugs market remained historically at high levels from 2018 to 2023. Disease-modifying anti-rheumatic drugs sub-segment under the Drug class category generated the largest revenue in 2018. This market research and growth report includes in-depth information on the key drivers, trends, and challenges during the forecasted period.

Market Share

For More Highlights About this Report, Download Free Sample in a Minute

Market Segmentation

Drug Class Segment

The market share growth by the disease-modifying anti-rheumatic drugs segment will be significant during the forecast period. Disease-modifying anti-rheumatic drugs (DMARDs) contain methotrexate, sulfasalazine, leflunomide, etanercept, and infliximab. Nonsteroidal anti-inflammatory drugs (NSAIDs) and DMARDs both relieve the symptoms of active rheumatoid arthritis, but only DMARDs have been proven to affect the course of the illness and improve radiological results. Rheumatoid arthritis is impacted differently and maybe more slowly by DMARDs.

Get a glance at the market contribution of various segments Download the PDF Sample

The disease-modifying anti-rheumatic drugs segment was valued at USD 20.53 billion in 2018. Early DMARD treatment can slow or stop the progression of RA and lessen the chance of joints suffering persistent, incapacitating damage. DMARDs target particular immune cell subsets and the cytokines they release. Consequently, the disease-modifying anti-rheumatic drugs segment is expected to grow at a rapid rate and drive the growth of the global market during the forecast period.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America is the primary market with the existence of leading market players for RA drugs, including AbbVie, Amgen, and Johnson and Johnson. Another factor that contributes to the significant market share of North America is the initiatives by organizations, such as the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the North American College of Rheumatology. Furthermore, in North America, the US has the maximum share, followed by Canada and Mexico. The US has the maximum RA patient pool in North America due to high cases of RA, which in turn will drive the growth of the regional market during the forecast period.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage. The arthritis market is witnessing growth due to the increasing number of patients experiencing the debilitating effects of this chronic disease. Among the various forms of arthritis, rheumatoid arthritis (RA) stands out for its severe symptoms and impact on daily life. Effective therapies and treatments are essential to manage the pain and inflammation associated with RA. As the number of individuals affected by arthritis continues to rise, there's a growing demand for innovative treatment options to alleviate symptoms and improve quality of life. Therefore, the market for arthritis therapies is poised for expansion to meet the evolving needs of patients grappling with this chronic condition.

Market Driver

Rising cases of RA and the focus on an increasing number of rheumatologists are the key factors driving market growth. RA is one of the most prevalent diseases across the globe. According to the National Library of Medicine, an estimated 17.6 million people had RA globally in 2020. The high number of cases of RA is expected to positively affect the growth of the market globally. Rheumatologists are physicians who are experienced in the diagnosis and treatment of arthritis and other diseases of the joints, muscles, and bones. The number and availability of rheumatologists should be increased to meet the demands of patients.

Furthermore, there are several associations that include rheumatology specialists, such as the Indian Rheumatology Association (IRA). IRA aims to fight against arthritis by means of regular scientific workshops, conferences, symposia, and special interest groups. Such associations are increasingly emerging across the world. Hence, the growing cases of RA and the focus on an increasing number of rheumatologists are anticipated to drive the growth of the market during the forecast period.

Market Trends

The use of biologics/biosimilars for the treatment of RA is the primary trend shaping market growth. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as profitable molecules for the successful treatment of RA. Also, biosimilars, which are replicas of biologics, are available at low prices and will likely invade the market. HUMIRA, Enbrel, CIMZIA, ACTEMRA, and SIMPONI are examples of some of the trending biologics that have shown promising results and are prescribed as a first-line treatment for diabetes.

Moreover, biosimilar therapy is still under development, and it may take a couple of years to get approval from regulatory authorities. Hence, the use of biologics/biosimilars for the treatment of RA is expected to positively affect the growth of the global market during the forecast period.

Market Challenge

Low access to healthcare due to social stigma is a challenge that affects market growth. Social stigmas associated with RA are primarily due to physical deformities and functional limitations in RA patients. Patients face anticipated stigma from co-workers, friends, and healthcare providers. This is often negatively associated with mental well-being and medication adherence. Social stigma can be a hurdle for various social groups that cannot gain access to healthcare facilities. Stress due to social stigma acts as a trigger for exacerbations of the disease.

Furthermore, various strategies are being adopted to tackle stigmas at the patient level. It involves initiating discussions with physicians to dispel misconceptions about the disease, align treatment expectations, and readjust disease management. The other steps include an increase in public awareness regarding the disease by government organizations and patient advocacy groups. Hence, the low access to healthcare due to social stigma is expected to impede the growth of the market during the forecast period.

Who are the major players in the Rheumatoid Arthritis Drugs Market?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc.: The company offers rheumatoid arthritis drugs namely Rinvoq that demonstrate both strong clinical performance and benefits to patients.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Analyst Overview

The Global Rheumatoid Arthritis Drugs Market is witnessing significant prevalence and a notable growth rate due to the increasing population affected by the condition. Various therapies are being developed to address the underlying inflammation and associated pain, targeting the immune system with medications such as corticosteroids and TNF inhibitors. Achieving remission is a primary goal, although some treatments may have side effects. Osteoarthritis is also a concern addressed by pharmaceutical companies through innovative solutions. The market includes biosimilars and biopharmaceuticals, with notable drugs like Cyltezo and Humira approved by the United States Food and Drug Administration. Additionally, NSAIDs and DMARDs play crucial roles in managing symptoms. Ongoing research, as published in journals like Rheumatology International and Frontiers in Immunology, continues to drive advancements in arthritis treatment.

Rheumatoid Arthritis Drugs Market Scope
Report Coverage	Details
Page number	162
Base year	2023
Historic period	2018 - 2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 7.5%
Market growth 2024-2028	USD 16045.12 million
Market structure	Fragmented
YoY growth 2023-2024(%)	6.4
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 39%
Key countries	US, UK, Germany, France, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor Biopharma Holdings Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA
Market dynamics	Market growth and trends, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download PDF Sample

What are the Key Data Covered in this Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
Precise estimation of the size of the market size and its contribution of the market in focus to the parent market
Accurate predictions about upcoming trends and changes in consumer behaviour
Market growth analysis industry across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about companies
Market forecasting of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global rheumatoid arthritis drugs market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global rheumatoid arthritis drugs market 2018 - 2022 ($ billion)

4.2 Drug Class Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Drug Class Segment 2018 - 2022 ($ billion)

4.3 Type Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
- Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)

6.2 Comparison by Drug Class
- Exhibit 32: Chart on Comparison by Drug Class
- Exhibit 33: Data Table on Comparison by Drug Class

6.3 Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028
- Exhibit 34: Chart on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)

6.4 Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028
- Exhibit 38: Chart on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)

6.5 Corticosteroids - Market size and forecast 2023-2028
- Exhibit 42: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ billion)
- Exhibit 43: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ billion)
- Exhibit 44: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)

6.6 Market opportunity by Drug Class
- Exhibit 46: Market opportunity by Drug Class ($ billion)
- Exhibit 47: Data Table on Market opportunity by Drug Class ($ billion)

7 Market Segmentation by Type

7.1 Market segments
- Exhibit 48: Chart on Type - Market share 2023-2028 (%)
- Exhibit 49: Data Table on Type - Market share 2023-2028 (%)

7.2 Comparison by Type
- Exhibit 50: Chart on Comparison by Type
- Exhibit 51: Data Table on Comparison by Type

7.3 Biologics - Market size and forecast 2023-2028
- Exhibit 52: Chart on Biologics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on Biologics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on Biologics - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Biologics - Year-over-year growth 2023-2028 (%)

7.4 Small Molecules - Market size and forecast 2023-2028
- Exhibit 56: Chart on Small Molecules - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on Small Molecules - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on Small Molecules - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Small Molecules - Year-over-year growth 2023-2028 (%)

7.5 Market opportunity by Type
- Exhibit 60: Market opportunity by Type ($ billion)
- Exhibit 61: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 UK - Market size and forecast 2023-2028
- Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.9 China - Market size and forecast 2023-2028
- Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)

9.10 Germany - Market size and forecast 2023-2028
- Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.11 France - Market size and forecast 2023-2028
- Exhibit 99: Chart on France - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on France - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on France - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on France - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ billion)
- Exhibit 104: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings

12.4 Amgen Inc.
- Exhibit 115: Amgen Inc. - Overview
- Exhibit 116: Amgen Inc. - Product / Service
- Exhibit 117: Amgen Inc. - Key offerings

12.5 Bristol Myers Squibb Co.
- Exhibit 118: Bristol Myers Squibb Co. - Overview
- Exhibit 119: Bristol Myers Squibb Co. - Product / Service
- Exhibit 120: Bristol Myers Squibb Co. - Key news
- Exhibit 121: Bristol Myers Squibb Co. - Key offerings

12.6 Eli Lilly and Co.
- Exhibit 122: Eli Lilly and Co. - Overview
- Exhibit 123: Eli Lilly and Co. - Product / Service
- Exhibit 124: Eli Lilly and Co. - Key news
- Exhibit 125: Eli Lilly and Co. - Key offerings

12.7 F. Hoffmann La Roche Ltd.
- Exhibit 126: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 127: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 128: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 129: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 130: F. Hoffmann La Roche Ltd. - Segment focus

12.8 Genor Biopharma Holdings Ltd.
- Exhibit 131: Genor Biopharma Holdings Ltd. - Overview
- Exhibit 132: Genor Biopharma Holdings Ltd. - Product / Service
- Exhibit 133: Genor Biopharma Holdings Ltd. - Key offerings

12.9 Gilead Sciences Inc.
- Exhibit 134: Gilead Sciences Inc. - Overview
- Exhibit 135: Gilead Sciences Inc. - Product / Service
- Exhibit 136: Gilead Sciences Inc. - Key news
- Exhibit 137: Gilead Sciences Inc. - Key offerings

12.10 Johnson and Johnson
- Exhibit 138: Johnson and Johnson - Overview
- Exhibit 139: Johnson and Johnson - Business segments
- Exhibit 140: Johnson and Johnson - Key news
- Exhibit 141: Johnson and Johnson - Key offerings
- Exhibit 142: Johnson and Johnson - Segment focus

12.11 Kangstem Biotech Co. Ltd.
- Exhibit 143: Kangstem Biotech Co. Ltd. - Overview
- Exhibit 144: Kangstem Biotech Co. Ltd. - Product / Service
- Exhibit 145: Kangstem Biotech Co. Ltd. - Key offerings

12.12 Novartis AG
- Exhibit 146: Novartis AG - Overview
- Exhibit 147: Novartis AG - Business segments
- Exhibit 148: Novartis AG - Key offerings
- Exhibit 149: Novartis AG - Segment focus

12.13 Oryn Therapeutics
- Exhibit 150: Oryn Therapeutics - Overview
- Exhibit 151: Oryn Therapeutics - Product / Service
- Exhibit 152: Oryn Therapeutics - Key offerings

12.14 Pfizer Inc.
- Exhibit 153: Pfizer Inc. - Overview
- Exhibit 154: Pfizer Inc. - Product / Service
- Exhibit 155: Pfizer Inc. - Key news
- Exhibit 156: Pfizer Inc. - Key offerings

12.15 Sanofi
- Exhibit 157: Sanofi - Overview
- Exhibit 158: Sanofi - Business segments
- Exhibit 159: Sanofi - Key news
- Exhibit 160: Sanofi - Key offerings
- Exhibit 161: Sanofi - Segment focus

12.16 Sorrento Therapeutics Inc.
- Exhibit 162: Sorrento Therapeutics Inc. - Overview
- Exhibit 163: Sorrento Therapeutics Inc. - Business segments
- Exhibit 164: Sorrento Therapeutics Inc. - Key offerings
- Exhibit 165: Sorrento Therapeutics Inc. - Segment focus

12.17 UCB SA
- Exhibit 166: UCB SA - Overview
- Exhibit 167: UCB SA - Product / Service
- Exhibit 168: UCB SA - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 169: Inclusions checklist
- Exhibit 170: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 171: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 172: Research methodology
- Exhibit 173: Validation techniques employed for market sizing
- Exhibit 174: Information sources

13.5 List of abbreviations
- Exhibit 175: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

rheumatoid arthritis drugs market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis